Raymond James raised the firm’s price target on Omega Healthcare (OHI) to $46 from $42 and keeps an Outperform rating on the shares. The recession-resilient and defensive, needs-driven nature of healthcare is increasingly top of mind in the current uncertain environment, the analyst tells investors in a research note. Improving operator fundamentals, an accommodative cost of capital and capacity for accretive external growth, remain attractive attributes of Omega, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OHI:
- Omega Healthcare price target raised to $42 from $39 at Scotiabank
- MedaSync announces strategic investment from Omega Healthcare
- Omega Healthcare Investors Reports Strong Q2 2025 Results
- Omega Healthcare Investors’ Earnings Call Highlights Robust Growth
- Omega Healthcare’s Strong Q2 Performance and Strategic Moves Justify Buy Rating